CareLit · DOI-Nachweis · Nuklearmedizin - NuclearMedicine
FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
DOI 10.1055/a-2283-8417
Bibliografische Angaben
Nachweis in CareLit
Autor:innenChristoph-Ferdinand Wielenberg, Johannes Christian Fostitsch, Christian Volz, Reinhard Marks, Kerstin Michalski, Ralph Wäsch, Robert Zeiser, Juri Ruf, Philipp T Meyer, Claudius Klein
ZeitschriftNuklearmedizin - NuclearMedicine
Ausgabe04/2024
Jahrgang / SeitenJg. 63 · S. 252-258
Kernaussage aus der Literatur
Abstract-Vorschau
Abstract Chimeric antigen receptor (CAR) T-cell therapy has dramatically shifted the landscape of treatment especially for Non-Hodgkin-Lymphoma (NHL). This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis. We evaluated 34 patients with NHL who received a CAR T-cell therapy…
Zitieren
Zitierempfehlung
Christoph-Ferdinand Wielenberg, Johannes Christian Fostitsch, Christian Volz, Reinhard Marks, Kerstin Michalski, Ralph Wäsch, Robert Zeiser, Juri Ruf, Philipp T Meyer, Claudius Klein (2024) FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL). Nuklearmedizin - NuclearMedicine, 63 (04), 252-258. https://doi.org/10.1055/a-2283-8417
Mit CareLit weiterarbeiten